Screener
Axsome Therapeutics AXSM Balipodect — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
The Company accounted for the transaction as an acquisition of an asset, as substantially all the fair value of the assets acquired were concentrated in balipodect. The Company recorded a charge of $10.4 million in research and development expense, inclusive of the upfront payment and direct transaction costs.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's balipodect — research and development expense?
- Axsome Therapeutics (AXSM) reported balipodect — research and development expense of $10.4M in Q1 2026.
- What does balipodect — research and development expense mean?
- This captures the direct and allocated costs incurred specifically for the research and development activities of the Balipodect program, including clinical trials, manufacturing process development, and regulatory filings. It serves as a primary indicator of the company's investment intensity in this specific CNS therapeutic candidate. Tracking this expense helps evaluate the progress and resource commitment toward bringing the product to market.
Ask your AI about Axsome Therapeutics's balipodect — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude